Impella 2.5: the results of Circulation Research study

In the last days it has been published by Circulation Research, the journal of American Heart Association, a new study which confirms how the use of Impella 2.5 during high-risk percutaneous coronary intervention (HRPCI) can reduce the risk of acute kidney injury (AKI) even when those patients had preexisting kidney disease and low ejection fraction (EF).

Produced by Abiomed, Gada’s consolidated partner, the Impella 2.5 heart pump confirms its qualities in reducing risks of renal damage which may require dialysis or other complex treatments.